Literature DB >> 24213016

Soluble c-Met expression in the peritoneal fluid and serum of patients with different stages of endometriosis.

Nilofar KhoshdelRad1, Zivar Salehi, Farhad Mashayekhi, Oranus Abbasi, Ebrahim Mirzajani.   

Abstract

INTRODUCTION: Hepatocyte growth factor (HGF), also known as scatter factor, and its receptor c-Met have been shown to be implicated in endometriosis. HGF acts as a mitogen, motogen, and morphogen on endometrial epithelial cells. The expression of c-Met on human endometrial cells has been reported. Many proteins are proteolytically released from the surface by a process known as ectodomain shedding. The aim of this study was to determine the levels of soluble c-Met (s-cMet) in the peritoneal fluid (PF) and serum samples of patients with different stages of endometriosis.
MATERIAL AND METHODS: 39 PF and serum samples from normal healthy and 130 samples from different stages of patients with endometriosis (33 cases of stage I, 38 stage II, 30 stage III and 29 stage IV) were included in this study. Total protein concentration (TPC) and the level of s-cMet in the PF and serum were determined by Bio-Rad protein assay based on the Bradford dye procedure and enzyme-linked immunosorbent assay, respectively.
RESULTS: No significant change in the TPC was seen in the serum and PF of patients with endometriosis when compared with normal controls. Results obtained demonstrated that all PF and serum samples presented s-cMet expression, whereas, starting from stages I to IV endometriosis, a significant increase of s-cMet expression was observed as compared to controls.
CONCLUSION: The results of this study show that a high expression of s-cMet is correlated with advanced stages of endometriosis. It is also concluded that the detection of serum and PF s-cMet may be useful in classifying endometriosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24213016     DOI: 10.1007/s00404-013-3082-7

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  6 in total

Review 1.  Blood biomarkers for the non-invasive diagnosis of endometriosis.

Authors:  Vicki Nisenblat; Patrick M M Bossuyt; Rabia Shaikh; Cindy Farquhar; Vanessa Jordan; Carola S Scheffers; Ben Willem J Mol; Neil Johnson; M Louise Hull
Journal:  Cochrane Database Syst Rev       Date:  2016-05-01

2.  VASCULAR ENDOTHELIAL GROWTH FACTOR SERUM LEVELS IN WOMEN WITH ADVANCED ENDOMETRIOSIS.

Authors:  A Malutan; T Drugan; C Georgescu; R Ciortea; C Bucuri; A Bobric; M P Rada; D Mihu
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Jan-Mar       Impact factor: 0.877

3.  Soluble ligands for the NKG2D receptor are released during endometriosis and correlate with disease severity.

Authors:  Iñaki González-Foruria; Pietro Santulli; Sandrine Chouzenoux; Francisco Carmona; Frédéric Batteux; Charles Chapron
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

4.  Dual inhibition of RNAi therapeutic miR-26a-5p targeting cMet and immunotherapy against EGFR in endometrial cancer treatment.

Authors:  Yun Liu; Yixuan Cai; Yue Chang
Journal:  Ann Transl Med       Date:  2021-01

5.  Expression levels of MCP-1, HGF, and IGF-1 in endometriotic patients compared with non-endometriotic controls.

Authors:  Sahel Heidari; Roya Kolahdouz-Mohammadi; Sepideh Khodaverdi; Nader Tajik; Ali-Akbar Delbandi
Journal:  BMC Womens Health       Date:  2021-12-20       Impact factor: 2.809

Review 6.  Update on Biomarkers for the Detection of Endometriosis.

Authors:  Amelie Fassbender; Richard O Burney; Dorien F O; Thomas D'Hooghe; Linda Giudice
Journal:  Biomed Res Int       Date:  2015-07-09       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.